ShanXi C&Y Pharmaceutical Group Co.,LTD. (SHE:300254)

China flag China · Delayed Price · Currency is CNY
12.02
+0.72 (6.37%)
Apr 10, 2026, 11:39 AM CST
Market Cap2.89B +24.1%
Revenue (ttm)849.26M +1.6%
Net Income20.36M -75.5%
EPS0.08 -75.7%
Shares Out256.06M
PE Ratio135.40
Forward PEn/a
Dividendn/a
Ex-Dividend Daten/a
Volume16,943,500
Average Volume11,207,223
Open11.23
Previous Close11.30
Day's Range11.23 - 12.18
52-Week Range7.44 - 14.23
Beta0.48
RSI47.58
Earnings DateApr 28, 2026

About SHE:300254

ShanXi C&Y Pharmaceutical Group Co.,LTD. engages in the research, development, production, and sale of medicine and health food products. It provides anti-infective drugs, anti-allergic drugs, respiratory drugs, urinary system drugs, kidney disease drugs, children's drugs, cardiovascular and cerebrovascular drugs, anti-depressants, medicines, pharmaceutical raw materials, and intermediates, commerce, etc. The company’s product portfolio includes Fosfomycin tromethamine powder, Ebastine tablets, Tamsulosin hydrochloride sustained release capsule... [Read more]

Sector Healthcare
Founded 2005
Employees 1,196
Stock Exchange Shenzhen Stock Exchange
Ticker Symbol 300254
Full Company Profile

Financial Performance

In 2024, SHE:300254's revenue was 846.61 million, an increase of 5.92% compared to the previous year's 799.31 million. Earnings were 42.19 million, an increase of 67.45%.

Financial Statements